Psychiatric care in the United States is scattered across a dozen specialties that rarely talk to each other. Salma Health just raised $80 million to build the thing that connects them.

The Series A, led by Mubadala Capital and ARCH Venture Partners with participation from Lingotto Horizon and Averin Capital, will fund an expansion of the company’s integrated brain health centers — clinics that combine psychiatry, neurology, and neuropsychiatry under one roof, powered by a proprietary AI platform the company calls Brain Health OS.

The model is part clinical, part computational. Patients receive deep profiling across demographic, neural, physiological, and digital biomarkers. Brain Health OS then drives diagnostics, treatment selection, and care coordination, routing patients to the right combination of pharmacotherapy, psychotherapy, transcranial magnetic stimulation (TMS), esketamine, or SAINT neuromodulation — an FDA-cleared protocol that can produce rapid antidepressant effects in days rather than weeks.

SAINT is the clinical anchor. Co-developed by CMO Brandon Bentzley and Stanford’s Nolan Williams, the protocol delivers accelerated, patterned TMS that has shown remission rates in treatment-resistant depression that conventional approaches can’t match. Salma’s Orange County clinic bears Williams’ name.

The company currently operates centers in San Diego, Orange County, Fremont, and Berkeley, with plans to expand across the US. Its HIPAA-compliant research infrastructure also positions it as a site network for pharmaceutical and device trials — a revenue line that could matter as the neuromodulation pipeline thickens.

The bet here isn’t on a single device or molecule. It’s on the idea that brain disorders need an integrated delivery system more than they need another point solution. If Salma can prove that AI-coordinated, multi-modal brain care produces better outcomes at scale, the $80 million will look like a down payment.